Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03456063 · ClinicalTrials.gov registry record · Phase 3
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
A Phase 3 study of Non-Small Cell Lung, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 453
- Enrollment target
- 20
- Study locations
NCT03456063 is a Phase 3 study of Non-Small Cell Lung that has completed, run by Hoffmann-La Roche. The registered enrollment target is 453 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT03456063, a Phase 3 study of Non-Small Cell Lung, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 453 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Nab-paclitaxel
- DRUG Placebo Comparator
- DRUG Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Study Locations (20)
California
- USC Norris Cancer Center - Los Angeles
- The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange - Orange
- UC Davis Cancer Center - Sacramento
- Scripps Clinic - San Diego
Michigan
- University of Michigan - Ann Arbor
- Brighton Center for Specialty Care - Brighton
- Barbara Ann Karmanos Cancer Institute - Detroit
Colorado
- National Jewish Health - Denver
- Rocky Mountain Cancer Center - Denver
District of Columbia
- Georgetown University - Washington D.C.
- Washington Cancer Institute - Washington D.C.
Minnesota
- Minnesota Oncology Minneapolis - Minneapolis
- Mayo Clinic - Rochester - Rochester
New York
- Northwell Health - Lake Success
- NYU Winthrop Hospital - Mineola
Arizona
- Arizona Oncology - Tucson
Illinois
- Illinois Cancer Care - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2018-04-24 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03456063
The ClinicalTrials.gov registry entry for NCT03456063 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 453 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03456063 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Michigan, Colorado.
Frequently Asked Questions
What is clinical trial NCT03456063 about?
NCT03456063 is a clinical study titled "A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)". This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB ...
What is the current status of trial NCT03456063?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 453 participants. The study started on 2018-04-24. Estimated completion is 2025-12-31.
What conditions does trial NCT03456063 study?
This clinical trial studies the following conditions: Non-Small Cell Lung.
What interventions are being tested in trial NCT03456063?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Nab-paclitaxel (DRUG), Placebo Comparator (DRUG), Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody (DRUG).
Who is sponsoring clinical trial NCT03456063?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03456063 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.